GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (OCSE:PEG) » Definitions » Capex-to-Operating-Income

Pharma Equity Group A/S (OCSE:PEG) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group A/S Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Pharma Equity Group A/S's Capital Expenditure for the three months ended in Mar. 2024 was kr0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was kr-6.83 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Pharma Equity Group A/S Capex-to-Operating-Income Historical Data

The historical data trend for Pharma Equity Group A/S's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S Capex-to-Operating-Income Chart

Pharma Equity Group A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharma Equity Group A/S Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pharma Equity Group A/S's Capex-to-Operating-Income

For the Biotechnology subindustry, Pharma Equity Group A/S's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group A/S's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group A/S's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group A/S's Capex-to-Operating-Income falls into.



Pharma Equity Group A/S Capex-to-Operating-Income Calculation

Pharma Equity Group A/S's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.073) / -25.294
=N/A

Pharma Equity Group A/S's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -6.828
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharma Equity Group A/S  (OCSE:PEG) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Pharma Equity Group A/S Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group A/S (OCSE:PEG) Business Description

Traded in Other Exchanges
N/A
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.